US › Healthcare

Greenwich Lifesciences Inc (GLSI)

US · Healthcare · Biotechnology

$18.39+17.66%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.9M

EPS

$-0.27

EPS estimate

$-0.33

EPS came in at -0.27 against a street estimate of -0.33 — a beat of 18.2%.

Key statistics

Market cap

$221.1M

Forward P/E

0.0

P/B

70.78

Book value

$0.21

EPS (TTM)

$-1.58

52-week high

$34.10

52-week low

$7.78

50-day MA

$16.54

200-day MA

$21.19

Beta

1.46

Analyst view

Analysts rate Greenwich Lifesciences Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $57.00.

Shareholding

Insiders

47.91%

Institutions

12.25%

Largest institutional holders

Fund	Stake
BlackRock Inc	2.96%
Vanguard Capital Management, LLC	2.03%
Geode Capital Management, LLC	1.06%
State Street Corp	0.91%
Nuveen, LLC	0.60%
Northern Trust Corp	0.51%
Vanguard Portfolio Management, LLC	0.40%
Bank of New York Mellon Corp	0.32%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Greenwich Lifesciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.